



## Table of Contents

Volume 100, Issue 9: September 2015

### Cover Figure

---

Artistic image based on the guideline article on myeloproliferative neoplasms  
(Image created by [www.somersault1824.com](http://www.somersault1824.com))

### Editorials

---

- 1103** Legacy of blood: does prasugrel inhibit megakaryocytes and do juvenile platelets inherit this inhibition?  
*Carlos G. Santos-Gallego, et al.*
- 1105** The FLAM regimen: revisiting time sequential induction therapy for patients with poor-risk acute myeloid leukemia  
*Steven Knapper, et al.*

### Review Article

---

- 1108** Environmental determinants of severity in sickle cell disease  
*Sanjay Tewari, et al.*

### Guideline Article

---

- 1117** An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms  
*Tariq I. Mughal, et al.*

### Articles

---

#### *Platelet Biology & its Disorders*

- 1131** Gradual increase in thrombogenicity of juvenile platelets formed upon offset of prasugrel medication  
*Constance C.F.M.J. Baaten, et al.*

#### *Myeloproliferative Disorders*

- 1139** A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis  
*Alessandro M. Vannucchi, et al.*

#### *Chronic Myeloid Leukemia*

- 1146** Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia  
*Gabriele Gugliotta, et al.*

#### *Acute Myeloid Leukemia*

- 1151** Recurrent deletions of *IKZF1* in pediatric acute myeloid leukemia  
*Jasmijn D.E. de Rooij, et al.*



**1160** Differential hypoxic regulation of the microRNA-146a/CXCR4 pathway in normal and leukemic monocytic cells: impact on response to chemotherapy  
*Isabella Spinello, et al.*

**1172** Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) *versus* cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia  
*Joshua F. Zeidner, et al.*

#### *Chronic Lymphocytic Leukemia*

**1180** Renal complications in chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis: the Mayo Clinic experience  
*Paolo Strati, et al.*

#### *Lymphoproliferative Syndromes*

**1189** Deregulation of Fas ligand expression as a novel cause of autoimmune lymphoproliferative syndrome-like disease  
*Schafiq Nabhani, et al.*

#### *Non-Hodgkin Lymphoma*

**1199** Concomitant systemic and central nervous system non-Hodgkin lymphoma: the role of consolidation in terms of high dose therapy and autologous stem cell transplantation. A 60-case retrospective study from LYSA and the LOC network  
*Gandhi Damaj, et al.*

#### *Plasma Cell Disorders*

**1207** Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: results of the randomized AZABACHE Spanish trial  
*Ramón García-Sanz, et al.*

**1214** Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120)  
*Rashid Khan, et al.*

#### *Stem Cell Transplantation*

**1222** Efficacy of immune suppression tapering in treating relapse after reduced intensity allogeneic stem cell transplantation  
*Natasha Kekre, et al.*

**1228** Predictive models for ocular chronic graft-*versus*-host disease diagnosis and disease activity in transplant clinical practice  
*Lauren M. Curtis, et al.*

## Letters to the Editor

Letters are available online only at [www.haematologica.org/content/100/9.toc](http://www.haematologica.org/content/100/9.toc)

**e334** Mice are poor heme absorbers and do not require intestinal *Hmox1* for dietary heme iron assimilation  
*Carine Fillebeen, et al.*  
<http://www.haematologica.org/content/100/9/e334>

**e338** Personalized reference intervals for platelet count reduce the number of subjects with unexplained thrombocytopenia  
*Carlo Zaninetti, et al.*  
<http://www.haematologica.org/content/100/9/e338>

**e341** Flow cytometric detection of MPL (CD110) as a diagnostic tool for differentiation of congenital thrombocytopenias  
*Matthias Ballmaier, et al.*  
<http://www.haematologica.org/content/100/9/e341>

**e345** Repeat course of rabbit antithymocyte globulin as salvage following initial therapy with rabbit antithymocyte globulin in acquired aplastic anemia  
*Diego V. Clé, et al.*  
<http://www.haematologica.org/content/100/9/e345>



- e348** The effects of JAK inhibitor therapy upon novel markers of thrombosis in myeloproliferative neoplasms  
*Clodagh Keohane, et al.*  
<http://www.haematologica.org/content/100/9/e348>
- e351** Adverse prognostic effect of homozygous *TET2* mutation on the relapse risk of acute myeloid leukemia in patients of normal karyotype  
*Jae-Sook Ahn, et al.*  
<http://www.haematologica.org/content/100/9/e351>
- e354** *BCR-ABL1*-like cases in pediatric acute lymphoblastic leukemia: a comparison between DCOG/Erasmus MC and COG/St. Jude signatures  
*Judith M. Boer, et al.*  
<http://www.haematologica.org/content/100/9/e354>
- e358** Immunohistochemical differentiation between follicular lymphoma and nodal marginal zone lymphoma – combined performance of multiple markers  
*Michiel van den Brand, et al.*  
<http://www.haematologica.org/content/100/9/e358>
- e361** Angioimmunoblastic T-cell lymphoma is the most common T-cell lymphoma in two distinct French information data sets  
*Laurence de Leval, et al.*  
<http://www.haematologica.org/content/100/9/e361>
- e365** ALK-negative anaplastic large cell lymphoma is sensitive to bortezomib through Noxa upregulation and release of Bax from Bcl-2  
*Saskia A.G.M. Cillessen, et al.*  
<http://www.haematologica.org/content/100/9/e366>
- e369** The utility of mRNA analysis in defining SOX11 expression levels in mantle cell lymphoma and reactive lymph nodes  
*Martin Lord, et al.*  
<http://www.haematologica.org/content/100/9/e369>
- e373** Management of carbapenem resistant *Klebsiella pneumoniae* infections in stem cell transplant recipients: an Italian multidisciplinary consensus statement  
*Corrado Girmenia, et al.*  
<http://www.haematologica.org/content/100/9/e373>

## Comments

Comments are available online only at [www.haematologica.org/content/100/9.toc](http://www.haematologica.org/content/100/9.toc)

- e377** PACE4 (PCSK6): another proprotein convertase link to iron homeostasis?  
*Johann Guillemot and Nabil G. Seidah*  
<http://www.haematologica.org/content/100/9/e377>
- e378** Comment on: "The impact of category, cytopathology and cytogenetics on development and progression of clonal and malignant myeloid transformation in inherited bone marrow failure syndromes"  
*Blanche P. Alter and Philip S. Rosenberg*  
<http://www.haematologica.org/content/100/9/e378>
- e379** Comment on "Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma"  
*Simon J. Harrison, et al.*  
<http://www.haematologica.org/content/100/9/e379>
- e380** Comment on: PACE4 (PCSK6): another proprotein convertase linked to iron homeostasis?  
*Alessia Paganì, et al.*  
<http://www.haematologica.org/content/100/9/e380>
- e381** Response to comments from Drs. Alter and Rosenberg  
*Yigal Dror and Michaela Cada*  
<http://www.haematologica.org/content/100/9/e381>